Create Free Account

By creating account you will get access to hot stocks & personalised emails

Merck & Company Inc

Healthcare US MRK

99.4502USD
1.11(1.13%)

Last update at 2024-12-19T18:54:00Z

Day Range

97.8299.56
LowHigh

52 Week Range

98.43117.20
LowHigh

Fundamentals

  • Previous Close 98.34
  • Market Cap272913.96M
  • Volume5316393
  • P/E Ratio59.83
  • Dividend Yield2.86%
  • EBITDA12934.00M
  • Revenue TTM59315.00M
  • Revenue Per Share TTM23.38
  • Gross Profit TTM 42077.00M
  • Diluted EPS TTM1.80

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 16444.00M 13879.00M 8791.00M 11464.00M 8701.00M
Minority interest -7.00000M 691.00M 15.00M -66.00000M -27.00000M
Net income 14519.00M 13049.00M 7067.00M 9843.00M 6220.00M
Selling general administrative 9772.00M 9293.00M 10468.00M 10615.00M 10102.00M
Selling and marketing expenses - - - - -
Gross profit 41872.00M 35078.00M 32509.00M 32728.00M 28785.00M
Reconciled depreciation 3909.00M 3214.00M 3625.00M 3652.00M 4519.00M
Ebit 14710.00M 10646.00M 5436.00M 9227.00M 5731.00M
Ebitda 18619.00M 13860.00M 9061.00M 12879.00M 10250.00M
Depreciation and amortization 3909.00M 3214.00M 3625.00M 3652.00M 4519.00M
Non operating income net other -1501.00000M 1341.00M 886.00M -139.00000M 402.00M
Operating income 14710.00M 10646.00M 5436.00M 9227.00M 8931.00M
Other operating expenses 41001.00M 35505.00M 39511.00M 34599.00M 33363.00M
Interest expense 962.00M 806.00M 831.00M 893.00M 772.00M
Tax provision 1918.00M 1521.00M 1709.00M 1687.00M 2508.00M
Interest income 1348.00M 1884.00M 59.00M 274.00M 343.00M
Net interest income -805.00000M -770.00000M -772.00000M -619.00000M -429.00000M
Extraordinary items 0.00000M 704.00M 2548.00M -117.00000M -289.00000M
Non recurring 337.00M 661.00M 578.00M 638.00M 632.00M
Other items - - - - -
Income tax expense 1918.00M 1521.00M 1709.00M 1687.00M 2508.00M
Total revenue 59283.00M 48704.00M 47994.00M 46840.00M 42294.00M
Total operating expenses 23590.00M 21879.00M 24026.00M 20487.00M 19854.00M
Cost of revenue 17411.00M 13626.00M 15485.00M 14112.00M 13509.00M
Total other income expense net 1734.00M 3233.00M 3355.00M 2237.00M 199.00M
Discontinued operations - 704.00M 704.00M 704.00M 704.00M
Net income from continuing ops 14526.00M 12358.00M 7082.00M 9777.00M 6193.00M
Net income applicable to common shares 14519.00M 13049.00M 7067.00M 9843.00M 6220.00M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 109160.00M 105694.00M 91588.00M 84397.00M 82637.00M
Intangible assets 20269.00M 22933.00M 14604.00M 14196.00M 11431.00M
Earning assets - - - - -
Other current assets 7169.00M 6987.00M 5541.00M 4277.00M 4500.00M
Total liab 63102.00M 67437.00M 66184.00M 58396.00M 55755.00M
Total stockholder equity 45991.00M 38184.00M 25317.00M 25907.00M 26701.00M
Deferred long term liab 1795.00M 3441.00M 1015.00M 1470.00M 1702.00M
Other current liab 18029.00M 16851.00M 16302.00M 14872.00M 13580.00M
Common stock 1788.00M 1788.00M 1788.00M 1788.00M 1788.00M
Capital stock 1788.00M 1788.00M 1788.00M 1788.00M 1788.00M
Retained earnings 61081.00M 53696.00M 47362.00M 46602.00M 42579.00M
Other liab 9105.00M 11650.00M 12135.00M 12672.00M 13662.00M
Good will 21204.00M 21264.00M 20238.00M 19425.00M 18253.00M
Other assets 7350.00M 9400.00M 7846.00M 5263.00M 5313.00M
Cash 12694.00M 8096.00M 8062.00M 9676.00M 7965.00M
Cash and equivalents 12694.00M 8096.00M 8062.00M 9676.00M 7965.00M
Total current liabilities 24239.00M 23872.00M 27327.00M 22220.00M 22206.00M
Current deferred revenue - - 1015.00M - -
Net debt 17997.00M 25006.00M 23729.00M 16670.00M 17149.00M
Short term debt 1946.00M 2412.00M 6431.00M 3610.00M 5308.00M
Short long term debt 1946.00M 2412.00M 6431.00M 3610.00M 5308.00M
Short long term debt total 30691.00M 33102.00M 31791.00M 26346.00M 25114.00M
Other stockholder equity -12110.00000M -12871.00000M -17199.00000M -16290.00000M -12121.00000M
Property plant equipment 21422.00M 19279.00M 17986.00M 15053.00M 13291.00M
Total current assets 35722.00M 30266.00M 27764.00M 27483.00M 25875.00M
Long term investments 1015.00M 370.00M 785.00M 1469.00M 6233.00M
Net tangible assets 4518.00M 3548.00M -9525.00000M -7714.00000M -2983.00000M
Short term investments 498.00M - 785.00M 774.00M 899.00M
Net receivables 9450.00M 9230.00M 7851.00M 6778.00M 7071.00M
Long term debt 28745.00M 30690.00M 25360.00M 22736.00M 19806.00M
Inventory 5911.00M 5953.00M 6310.00M 5978.00M 5440.00M
Accounts payable 4264.00M 4609.00M 4594.00M 3738.00M 3318.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity 67.00M 73.00M 87.00M 94.00M 181.00M
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -4768.00000M -4429.00000M -6634.00000M -6193.00000M -5545.00000M
Additional paid in capital - - - - -
Common stock total equity 1788.00M 1788.00M 1788.00M 1788.00M 1788.00M
Preferred stock total equity - - - - -
Retained earnings total equity 61081.00M 53696.00M 47362.00M 46602.00M 42579.00M
Treasury stock - -57109.00000M -56787.00000M -55950.00000M -50929.00000M
Accumulated amortization - - - - -
Non currrent assets other 7733.00M 8141.00M 9196.00M 5301.00M 5852.00M
Deferred long term asset charges - - - - -
Non current assets total 73438.00M 75428.00M 63824.00M 56914.00M 56762.00M
Capital lease obligations - - - - -
Long term debt total 28745.00M 30690.00M 25360.00M 22736.00M 19806.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -483.00000M 1025.00M 1717.00M 5420.00M 7258.00M
Change to liabilities -504.00000M 626.00M -307.00000M -1821.00000M 450.00M
Total cashflows from investing activities -4960.00000M -16421.00000M -9443.00000M -2629.00000M 4314.00M
Net borrowings -2251.00000M 1631.00M 5011.00M 1248.00M 837.00M
Total cash from financing activities -9119.00000M 2593.00M -2832.00000M -8861.00000M -13160.00000M
Change to operating activities -2068.00000M -997.00000M -4017.00000M 107.00M -1281.00000M
Net income 14526.00M 12358.00M 7082.00M 9777.00M 6193.00M
Change in cash 4606.00M 14.00M -1769.00000M 1967.00M 1871.00M
Begin period cash flow 8167.00M 8153.00M 9934.00M 7967.00M 6096.00M
End period cash flow 12773.00M 8167.00M 8165.00M 9934.00M 7967.00M
Total cash from operating activities 19095.00M 14109.00M 10253.00M 13440.00M 10922.00M
Issuance of capital stock - - - - -
Depreciation 3909.00M 3214.00M 3625.00M 3652.00M 4519.00M
Other cashflows from investing activities -89.00000M -13132.00000M -6476.00000M -4576.00000M -329.00000M
Dividends paid -7012.00000M -6610.00000M -6215.00000M -5695.00000M 5172.00M
Change to inventory -161.00000M -674.00000M -855.00000M -508.00000M -911.00000M
Change to account receivables -644.00000M -2033.00000M -1002.00000M 294.00M -418.00000M
Sale purchase of stock 384.00M -840.00000M -1281.00000M -4780.00000M -9091.00000M
Other cashflows from financing activities 144.00M 8714.00M -436.00000M 1614.00M -325.00000M
Change to netincome 2023.00M 2760.00M 1476.00M 2078.00M 1113.00M
Capital expenditures 4388.00M 4448.00M 4684.00M 3473.00M 2615.00M
Change receivables -644.00000M -2033.00000M -1002.00000M 294.00M -418.00000M
Cash flows other operating 14472.00M 10216.00M 234.00M -32.00000M -24.00000M
Exchange rate changes - - - - -
Cash and cash equivalents changes 5016.00M -202.00000M -2022.00000M 1950.00M 2076.00M
Change in working capital -2782.00000M -3839.00000M -4590.00000M -2067.00000M -1553.00000M
Stock based compensation 541.00M 479.00M 475.00M 417.00M 348.00M
Other non cash items 4469.00M 1710.00M 4329.00M 2217.00M 1924.00M
Free cash flow 14707.00M 9661.00M 5569.00M 9967.00M 8307.00M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - General

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
MRK
Merck & Company Inc		 1.11 1.13% 99.45 59.83 12.33 4.50 6.47 4.94 23.79
LLY
Eli Lilly and Company		 -5.84 0.76% 758.87 103.14 46.73 16.88 48.24 17.43 69.11
JNJ
Johnson & Johnson		 -0.09 0.06% 144.66 29.17 14.33 3.74 5.18 3.80 15.22
ABBV
AbbVie Inc		 0.02 0.01% 173.04 61.52 14.86 5.62 51.62 6.76 20.58
AZN
AstraZeneca PLC ADR		 0.03 0.04% 64.67 38.69 16.31 4.67 5.46 5.20 17.74

Reports Covered

Stock Research & News

View All

Profile

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV, as well as a collaboration with Bionomics to identify novel a7 nAChR PAMs suitable for the treatment of cognitive disorder; and clinical trial collaboration and supply agreement with Ankyra Therapeutics to evaluate ANK-101 in combination with KEYTRUDA (pembrolizumab) in patients with advanced solid tumors, as well as a clinical trial collaboration and supply agreement with Phanes Therapeutics, Inc. to evaluate PT886 in combination with KEYTRUDA for the treatment of claudin 18.2 positive gastric or gastroesophageal junction adenocarcinomas, as well as a development and commercialization agreement with Daiichi Sankyo Company, Limited to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates and a collaboration with HiberCell, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Merck & Company Inc

2000 Galloping Hill Road, Kenilworth, NJ, United States, 07033

Key Executives

Name Title Year Born
Mr. Robert M. Davis J.D. CEO & Chairman 1967
Ms. Caroline Litchfield Exec. VP & CFO 1969
Mr. Richard R. DeLuca Jr. Exec. VP & Pres of Merck Animal Health 1963
Dr. Dean Y. Li M.D., Ph.D. Exec. VP & Pres of Merck Research Laboratories 1962
Mr. David Michael Williams Exec. VP and Chief Information & Digital Officer 1969
Mr. Peter Dannenbaum VP of Investor Relations NA
Ms. Jennifer L. Zachary Exec. VP & Gen. Counsel 1978
Lisa LeCointe-Cephas Sr. VP and Chief Ethics & Compliance Officer 1982
Ms. Jennifer Mauer VP of Global Communications NA
Ms. Cristal N. Downing Exec. VP and Chief Communications & Public Affairs Officer 1969

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.